Orrick advised SFJ Pharmaceuticals on the deal. SFJ Pharmaceuticals (“SFJ”) announced its acquisition of assets related to Bentracimab, a drug with the potential to address a significant...
This content is for Standard 1 Year members only. LoginJoin Now